Kandalaft LE - Search Results

1

Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines.

Ahmed R, Sayegh N, Graciotti M, Kandalaft LE. Ahmed R, et al. Among authors: kandalaft le. Curr Opin Biotechnol. 2020 Oct;65:142-155. doi: 10.1016/j.copbio.2020.02.009. Epub 2020 Mar 30. Curr Opin Biotechnol. 2020. PMID: 32240923 Review.

2

Immunotherapy for ovarian cancer: recent advances and perspectives.

Zsiros E, Tanyi J, Balint K, Kandalaft LE. Zsiros E, et al. Among authors: kandalaft le. Curr Opin Oncol. 2014 Sep;26(5):492-500. doi: 10.1097/CCO.0000000000000111. Curr Opin Oncol. 2014. PMID: 25036883 Review.

3

Potential approaches for more successful dendritic cell-based immunotherapy.

Chiang CL, Balint K, Coukos G, Kandalaft LE. Chiang CL, et al. Among authors: kandalaft le. Expert Opin Biol Ther. 2015 Apr;15(4):569-82. doi: 10.1517/14712598.2015.1000298. Epub 2015 Jan 2. Expert Opin Biol Ther. 2015. PMID: 25553913 Review.

4

Personalized approaches to active immunotherapy in cancer.

Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE. Ophir E, et al. Among authors: kandalaft le. Biochim Biophys Acta. 2016 Jan;1865(1):72-82. doi: 10.1016/j.bbcan.2015.07.004. Epub 2015 Aug 1. Biochim Biophys Acta. 2016. PMID: 26241169 Review.

5

Cancer Vaccines in Ovarian Cancer: How Can We Improve?

Martin Lluesma S, Wolfer A, Harari A, Kandalaft LE. Martin Lluesma S, et al. Among authors: kandalaft le. Biomedicines. 2016 May 3;4(2):10. doi: 10.3390/biomedicines4020010. Biomedicines. 2016. PMID: 28536377 Free PMC article. Review.

6

A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.

Mookerjee A, Graciotti M, Kandalaft LE, Kandalaft L. Mookerjee A, et al. Among authors: kandalaft l, kandalaft le. Bioimpacts. 2018;8(3):211-221. doi: 10.15171/bi.2018.24. Epub 2018 Jun 10. Bioimpacts. 2018. PMID: 30211081 Free PMC article.

7

In vivo cancer vaccination: Which dendritic cells to target and how?

Chiang CL, Kandalaft LE. Chiang CL, et al. Among authors: kandalaft le. Cancer Treat Rev. 2018 Dec;71:88-101. doi: 10.1016/j.ctrv.2018.10.012. Epub 2018 Oct 25. Cancer Treat Rev. 2018. PMID: 30390423 Free PMC article. Review.

8

Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?

Martin Lluesma S, Graciotti M, Chiang CL, Kandalaft LE. Martin Lluesma S, et al. Among authors: kandalaft le. Vaccines (Basel). 2018 Nov 23;6(4):79. doi: 10.3390/vaccines6040079. Vaccines (Basel). 2018. PMID: 30477198 Free PMC article. Review.

9

IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine.

Mookerjee A, Graciotti M, Kandalaft LE. Mookerjee A, et al. Among authors: kandalaft le. Cancers (Basel). 2019 Jan 4;11(1):40. doi: 10.3390/cancers11010040. Cancers (Basel). 2019. PMID: 30621204 Free PMC article.

10

Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.

Mookerjee A, Graciotti M, Kandalaft LE. Mookerjee A, et al. Among authors: kandalaft le. Bioimpacts. 2019;9(1):65. doi: 10.15171/bi.2019.08. Epub 2019 Jan 12. Bioimpacts. 2019. PMID: 30788261 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

89 results

Search Page